A recent study published in JAMA highlighted the promising results of the RSVpreF vaccination in reducing cardiorespiratory hospitalizations among adults aged 60 and older. Conducted by a multi-institutional collaboration led by the Center for Translational Cardiology and Pragmatic Randomized Trials at Copenhagen University Hospital-Herlev and Gentofte, University of Copenhagen, this research provides critical insights into the potential benefits of vaccination for older adults, especially those with preexisting health conditions.

Overview of the Study

The study aimed to analyze the effectiveness of the RSVpreF vaccine against cardiorespiratory events, a pressing concern given the health hazards associated with respiratory syncytial virus (RSV) in the elderly population. Historically, RSV has been linked to serious pulmonary complications and elevated risks for those with preexisting cardiovascular disease. While previous clinical trials had focused primarily on RSV's role in lower respiratory tract illnesses, this research undertook a secondary analysis of cardiovascular outcomes during the DAN-RSV trial.

Study Design and Participants

A total of 131,276 participants from Denmark were involved in the study. They were randomly assigned in a 1:1 ratio to receive either the RSVpreF vaccination (n = 65,642) or no vaccine (control group; n = 65,634) during the winter season of 2024-2025. Key demographics included:

Characteristic RSVpreF Group Control Group
Mean Age (years) 69.4 69.4
Male (%) 50.3% 50.3%
Preexisting Cardiovascular Disease (%) 21.8% 21.8%

Results

The findings revealed a notable difference in the rates of all-cause cardiorespiratory hospitalization between the two groups. Specifically, the hospitalization rates were:

  • RSVpreF Group: 26.3 events per 1,000 participant-years
  • Control Group: 29.2 events per 1,000 participant-years

This translated to an absolute rate reduction of 2.90 per 1,000 participant-years, indicating a vaccine effectiveness of 9.9% (95% CI, 0.3%–18.7%; P = .04).

Specific Cardiovascular Outcomes

Although the RSVpreF vaccination demonstrated a significant reduction in cardiorespiratory hospitalizations, the rates of specific cardiovascular hospitalizations were less conclusive:

Outcome RSVpreF Group Control Group Vaccine Effectiveness
Cardiovascular Hospitalizations (events per 1,000 participant-years) 16.4 17.7 7.4% (95% CI, −5.5% to 18.8%; P = .24)
Stroke Hospitalizations 3.0 3.8 19.4% (95% CI, −8.6% to 40.4%; P = .14)

No statistically significant reductions were observed for other cardiovascular events such as myocardial infarction or heart failure hospitalization. Despite these limitations, the overall results indicate that the vaccine may confer important protective effects against severe respiratory complications in older adults.

Conclusion and Implications

The authors concluded that RSVpreF vaccination is associated with fewer all-cause cardiorespiratory hospitalizations in the targeted demographic of adults aged 60 and older. This research underscores the necessity for public health initiatives aimed at vaccinating older populations, particularly considering their vulnerability to complications stemming from respiratory infections. Furthermore, it supports the notion that immunization can lead to broader health benefits, potentially reducing severe cases of cardiorespiratory distress among older adults, especially those with existing cardiovascular conditions.

“The encouraging outcomes of our study highlight the importance of considering vaccination as a strategy to mitigate severe cardiorespiratory complications in older adults.” – Dr. Mats C. Højbjerg Lassen, Lead Researcher

Future Directions

  • Further studies should aim to explore the long-term benefits of RSV vaccination on cardiovascular outcomes.
  • Investigations into different age brackets and comorbidities will provide a clearer understanding of the vaccine's broader effects.
  • As the dynamics of viral infections evolve, ongoing immunization strategies should adapt to ensure optimal protection for vulnerable populations.

References

[1] Lassen, M. C. H., et al. (2025). Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults, JAMA.

[2] Chu, H. Y., et al. (2025). Shot Through the Heart—Can RSV Vaccination Reduce Risk of Cardiovascular Outcomes?, JAMA.

[3] Additional resources can be accessed through Medical Xpress.